Last reviewed · How we verify
RNA-loaded dendritic cell vaccine
At a glance
| Generic name | RNA-loaded dendritic cell vaccine |
|---|---|
| Sponsor | Gary Archer Ph.D. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma (PHASE3)
- RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. (PHASE1)
- A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer (PHASE1)
- Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (PHASE1)
- Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma (PHASE1)
- Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RNA-loaded dendritic cell vaccine CI brief — competitive landscape report
- RNA-loaded dendritic cell vaccine updates RSS · CI watch RSS
- Gary Archer Ph.D. portfolio CI